Table 2.
Comparison of baseline characteristics in patients with advanced hepatocellular carcinoma with and without hyper-progressive disease according to two different criteria
| Characteristic | TGR ≥ 2 or TGKR ≥ 2 | TGR ≥ 4 or TGKR ≥ 4 | ||||
|---|---|---|---|---|---|---|
|
HPD N = 8 |
Non-HPD N = 77 |
P-value |
HPD N = 5 |
Non-HPD N = 80 |
P-value | |
| Sex, male, n (%) | 7 (87.5) | 66 (85.7) | 1.000 | 5 (100) | 68 (85.0) | 1.000 |
| Age > 74 years, n (%) | 3 (37.5) | 38 (49.4) | 0.714 | 3 (60.0) | 38 (47.5) | 0.669 |
| HBV positive, n (%) | 1 (12.5) | 17 (22.1) | 1.000 | 0 (0.0) | 18 (22.5) | 0.579 |
| HCV positive, n (%) | 4 (50.0) | 21 (27.3) | 0.226 | 3 (60.0) | 22 (27.5) | 0.149 |
| Child–Pugh class A, n (%) | 7 (87.5) | 72 (93.5) | 0.458 | 5 (100) | 74 (92.5) | 1.000 |
| AFP > 400 ng/mL, n (%) | 3 (37.5) | 29 (37.7) | 1.000 | 2 (40.0) | 30 (37.5) | 1.000 |
| BCLC stage C, n (%) | 5 (62.5) | 47 (61.0) | 0.257 | 3 (60.0) | 49 (61.3) | 1.000 |
| Macrovascular invasion, n (%) | 1 (12.5) | 17 (22.1) | 1.000 | 0 (0.0) | 18 (22.5) | 0.579 |
| Extrahepatic spread, n (%) | 2 (25.0) | 33 (42.9) | 0.461 | 1 (20.0) | 34 (42.5) | 0.645 |
| Treatment line, 1st line, n (%) | 2 (25.0) | 37 (48.1) | 0.279 | 2 (40.0) | 37 (46.3) | 1.000 |
| ECOG-PS ≤ 1, n (%) | 8 (100) | 77 (100) | 1.000 | 5 (100) | 80 (100) | 1.000 |
| NLR ≥ 3.43, n (%) | 5 (62.5) | 30 (39.0) | 2.464 | 4 (80.0) | 31 (38.8) | 0.154 |
Abbreviations: HBV hepatitis B virus, HCV hepatitis C virus, AFP alpha-fetoprotein, BCLC Barcelona Clinic Liver Cancer, ECOG-PS Eastern Cooperative Oncology Group Performance Status, NLR neutrophil-to-lymphocyte ratio